company background image
0QCO logo

Pharming Group LSE:0QCO Stock Report

Last Price

€0.72

Market Cap

€471.5m

7D

-0.5%

1Y

-32.8%

Updated

22 Nov, 2024

Data

Company Financials +

0QCO Stock Overview

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. More details

0QCO fundamental analysis
Snowflake Score
Valuation6/6
Future Growth4/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Pharming Group N.V. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Pharming Group
Historical stock prices
Current Share Price€0.72
52 Week High€1.22
52 Week Low€0.65
Beta0.81
11 Month Change-14.63%
3 Month Change-1.55%
1 Year Change-32.84%
33 Year Change-2.74%
5 Year Change-49.98%
Change since IPO-92.84%

Recent News & Updates

Recent updates

Shareholder Returns

0QCOGB BiotechsGB Market
7D-0.5%-5.2%0.8%
1Y-32.8%-20.1%6.6%

Return vs Industry: 0QCO underperformed the UK Biotechs industry which returned -20.1% over the past year.

Return vs Market: 0QCO underperformed the UK Market which returned 6.6% over the past year.

Price Volatility

Is 0QCO's price volatile compared to industry and market?
0QCO volatility
0QCO Average Weekly Movement6.0%
Biotechs Industry Average Movement9.6%
Market Average Movement4.7%
10% most volatile stocks in GB Market10.3%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0QCO has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: 0QCO's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1988382Simon de Vrieswww.pharming.com

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Pharming Group N.V. Fundamentals Summary

How do Pharming Group's earnings and revenue compare to its market cap?
0QCO fundamental statistics
Market cap€471.46m
Earnings (TTM)-€17.11m
Revenue (TTM)€274.37m

1.8x

P/S Ratio

-28.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0QCO income statement (TTM)
RevenueUS$285.75m
Cost of RevenueUS$30.30m
Gross ProfitUS$255.44m
Other ExpensesUS$273.26m
Earnings-US$17.82m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.026
Gross Margin89.39%
Net Profit Margin-6.24%
Debt/Equity Ratio42.3%

How did 0QCO perform over the long term?

See historical performance and comparison